Actively Recruiting

Phase 2
Age: 12Years +
All Genders
NCT05664737

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia

Led by Bristol-Myers Squibb · Updated on 2026-03-24

189

Participants Needed

36

Research Sites

609 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the study is to evaluate the efficacy and safety of luspatercept plus best supportive care (BSC) vs placebo plus BSC on anemia in adult participants with α-thalassemia hemoglobin H (HbH) disease and determine the safety and drug levels in adolescent participants.

CONDITIONS

Official Title

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult participants aged 18 years or older with documented alpha-thalassemia hemoglobin H disease
  • Transfusion-dependent adults: at least 6 red blood cell units transfused in the 24 weeks before randomization
  • Non-transfusion-dependent adults: fewer than 6 red blood cell units transfused in the 24 weeks before randomization, no transfusions for at least 8 weeks prior unless for acute conditions, and mean baseline hemoglobin of 10 g/dL or less based on at least 2 measurements
  • Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 for adult participants
  • Adolescent participants aged 12 to less than 18 years with documented alpha-thalassemia hemoglobin H disease
  • Transfusion-dependent adolescents: at least 4 red blood cell events in the 24 weeks before enrollment with no transfusion-free period longer than 56 days during that time and history of regular transfusions for at least 2 years
  • Non-transfusion-dependent adolescents: fewer than 4 red blood cell events in the 24 weeks before enrollment, transfusion-free for at least 8 weeks prior, and mean baseline hemoglobin of 10 g/dL or less based on at least 2 measurements
  • Karnofsky (for age 16 years and older) or Lansky (for under 16 years) performance status score of 50 or higher at screening
Not Eligible

You will not qualify if you...

  • Diagnosis of alpha-thalassemia trait, Hb Bart hydrops, ATRx alpha-thalassemia, hemoglobin S/beta-thalassemia, myelodysplasia subtype anemia, or HbE homozygous beta gene mutation
  • Anemia caused by nutritional deficiency, chronic disease, autoimmune hemolytic anemia, or other hemolytic anemias
  • Hemolysis episodes unrelated to alpha-thalassemia within 8 weeks before randomization
  • Deep vein thrombosis, stroke, or other thromboembolic events requiring treatment within 24 weeks before randomization (except clogged catheters)
  • Uncontrolled hypertension exceeding Grade 1 blood pressure levels
  • Women who are pregnant, planning pregnancy during the study, or breastfeeding
  • Previous hematopoietic stem cell transplant or gene therapy (unless waiting period of 12 months is met)
  • Use of hydroxyurea treatment within 12 weeks for non-transfusion-dependent or 24 weeks for transfusion-dependent participants prior to enrollment
  • Extramedullary hematopoiesis complications requiring treatment during screening
  • Any medical or psychiatric condition that poses unacceptable risk or affects data interpretation according to the investigator
  • Other protocol-specified inclusion or exclusion criteria apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 36 locations

1

Local Institution - 0008

Halifax, Nova Scotia, Canada, B3K 6R8

Withdrawn

2

Sun Yat-sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, GD, China, 510120

Actively Recruiting

3

Nanfang Hospital of Southern Medical University

Guangzhou, GD, China, 510515

Actively Recruiting

4

The First People's Hospital of Foshan

Foshan, Guangdong, China, 528000

Actively Recruiting

5

Maoming People's Hospital

Maoming Shi, Guangdong, China, 525000

Actively Recruiting

6

Shenzhen Second People's Hospital

Shenzhen Shi, Guangdong, China, 518025

Actively Recruiting

7

Liuzhou People's Hospital

Liuzhou, Guangxi, China, 545006

Actively Recruiting

8

People's Liberation Army The 923rd Hospital

Nanning, GX, China, 530021

Actively Recruiting

9

Local Institution - 0011

Haikou, Hainan, China, 570203

Active, Not Recruiting

10

Local Institution - 0012

Kunming, Yunnan, China, 650032

Completed

11

Hainan General Hospital

Haikou, China, 570311

Actively Recruiting

12

The First Affiliated Hospital of Guangxi Medical University

Nanning, China, 530021

Actively Recruiting

13

Local Institution - 0005

Thessaloniki, B, Greece, 546 42

Withdrawn

14

Local Institution - 0007

Larissa, E, Greece, 412 21

Active, Not Recruiting

15

Local Institution - 0018

Rio, G, Greece, 265 04

Active, Not Recruiting

16

Local Institution - 0006

Athens, Greece, 115 27

Active, Not Recruiting

17

Local Institution - 0009

Goudi, Greece, 11527

Active, Not Recruiting

18

Local Institution - 0025

Hong Kong, HK, Hong Kong

Completed

19

Local Institution - 0024

Hong Kong Island, Hong Kong

Withdrawn

20

Local Institution - 0022

Cagliari, CA, Italy, 09121

Withdrawn

21

Local Institution - 0026

Genova, GE, Italy, 16128

Active, Not Recruiting

22

Local Institution - 0020

Orbassano, TO, Italy, 10043

Active, Not Recruiting

23

Local Institution - 0028

Naples, Italy, 80131

Active, Not Recruiting

24

"Universita degli Studi della Campania ""Luigi Vanvitelli"" - AOU - Clinica Pediatrica"

Naples, Italy, 80138

Actively Recruiting

25

Hospital Tunku Azizah

Kuala Lumpur, WP, Malaysia, 50586

Actively Recruiting

26

Hospital Sultanah Aminah

Johor Bahru, Malaysia, 80100

Actively Recruiting

27

Local Institution - 0035

Al-Ahsa, Saudi Arabia, 31982

Withdrawn

28

King Saud University (KSU) - College of Medicine

Riyadh, Saudi Arabia, 11411

Actively Recruiting

29

KK Women's and Children's Hospital

Singapore, Singapore, 229899

Actively Recruiting

30

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, KHH, Taiwan, 807

Actively Recruiting

31

National Taiwan University Hospital

Nan Gang Qu, TPE, Taiwan, 10002

Actively Recruiting

32

China Medical University Hospital

Taichung, TXG, Taiwan, 40447

Actively Recruiting

33

Siriraj Hospital

Bangkok Noi, Bangkok, Thailand, 10700

Actively Recruiting

34

Naresuan University Hospital

Mueang Phitsanulok, Thailand, 65000

Actively Recruiting

35

Hacettepe Üniversitesi Tıp Fakültesi

Altındağ, Turkey (Türkiye), 06230

Actively Recruiting

36

Istanbul Universitesi - Istanbul Tip Fakultesi (ITF) Hastanesi

Topkapı, Turkey (Türkiye), 34093

Actively Recruiting

Loading map...

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

CONTACT

F

First line of the email MUST contain NCT # and Site #.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia | DecenTrialz